Company Encyclopedia
View More
name
Jibeier Pharmaceutical
688566.SH
Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the drug research and development and production in China. The company’s products cover multiple therapeutic areas such as increasing white blood cells, fighting hypertension, enhancing immunity, treating joint diseases, fighting eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach and gastric diseases, and other diseases. In addition, the company offers its products in tablets, capsules, and eye drops forms.
3.159 T
688566.SHMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
B
PharmaceuticalsIndustry
Industry Ranking52/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE10.48%B
    • Profit Margin25.23%A
    • Gross Margin89.50%A
  • Growth ScoreC
    • Revenue YoY7.96%B
    • Net Profit YoY1.29%C
    • Total Assets YoY5.93%B
    • Net Assets YoY4.81%B
  • Cash ScoreC
    • Cash Flow Margin396.31%C
    • OCF YoY7.96%B
  • Operating ScoreC
    • Turnover0.37C
  • Debt ScoreA
    • Gearing Ratio10.22%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Jibeier Pharmaceutical: Results of Phase III Clinical Trial for New Antidepressant JJH201501 Released

    Jibeier Pharmaceutical announced that the Phase III clinical trial results of its antidepressant new drug JJH201501 have been released. The trial was designed as a randomized, double-blind, placebo-controlled, and positive-controlled study, with a total of 525 participants. The results showed that the 10mg and 15mg dosage groups had significantly better efficacy in treating depression compared to the placebo group, and were comparable to the 20mg group of hydrobromide vortioxetine tablets

    Zhitong·
    SH
    688566
    +0.55%
    Zhitong·
    SH
    688566
    +0.55%

    Caitong Securities: The demand for phosphonamide monomers will flourish, and multinational pharmaceutical companies' supply chain enterprises are expected to benefit

    Caitong Securities released a research report indicating that phosphoramidite monomers play a key role in the development of small nucleic acid drugs, and demand is expected to grow significantly in the future. According to predictions from sphericalinsights, global sales of nucleotides will reach USD 730 million in 2023, with China being the largest production market, primarily focused on exports. Small nucleic acid drugs are considered potential treatment options for various diseases due to their unique molecular structure and therapeutic mechanisms, and companies within the supply chains of multinational pharmaceutical companies are expected to benefit from this

    Zhitong·
    SH
    688566
    +0.55%
    SH
    688136
    +0.21%
    SZ
    002250
    +0.92%
    Zhitong·
    SH
    688566
    +0.55%
    SH
    688136
    +0.21%
    SZ
    002250
    +0.92%

    Jibeier Pharmaceutical: Application for the listing of the chemical raw material drug Gatifloxacin has been approved

    On October 23rd, Jibeier Pharmaceutical announced that the company recently received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration. The name of the chemical raw material is Gatifloxacin, which is the main ingredient in the company's Gatifloxacin eye drops. Gatifloxacin eye drops are mainly used for acute bacterial conjunctivitis caused by sensitive bacteria

    Zhitong·
    SH
    688566
    +0.55%
    Zhitong·
    SH
    688566
    +0.55%

    Jibeier Pharmaceutical: The investigational anti-tumor new drug injectable JJH201601 liposome has obtained approval for clinical trials

    Jibeier Pharmaceutical recently announced that its investigational anti-tumor new drug injectable JJH201601 liposome has received clinical trial approval from the National Medical Products Administration. The drug will be used in clinical trials in combination with cetuximab and/or toripalimab for advanced head and neck squamous cell carcinoma. JJH201601 liposome is a novel compound developed based on a liposome drug development technology platform

    Zhitong·
    SH
    688566
    +0.55%
    Zhitong·
    SH
    688566
    +0.55%

    Jibeier's director Hu Tao has cumulatively reduced his holdings by 1%

    According to the Zhitong Finance APP, Jibeier announced that the share reduction plan of the company's director Hu Tao has been completed, with a total reduction of 1.99 million shares, accounting for 1.00% of the company's total share capital

    Zhitong·
    SH
    688566
    +0.55%
    Zhitong·
    SH
    688566
    +0.55%
    © 2025 Longbridge｜Disclaimer